On this page

Telehealth partner metrics are the aggregate numbers a drugmaker uses to see how each telehealth and pharmacy partner in a direct-to-patient program turns visits into paid fills and refills: visit-to-consult rate, paid-fill rate, time to first fill, month-3 and month-6 refill rates, and cost per paid fill. They matter because a program can run through several partners at once, and cash-pay fills often fall outside insurance claims. Curve Compliance supports this measurement: in this method, partners report stripped-down step events, Curve credits each one to the original ad click, and the drugmaker receives aggregate results by channel, campaign and partner.

Book a call. Running a direct-to-patient program through several telehealth and pharmacy partners? Curve's team does the setup for the partner events and the campaign reporting, typically live in about a week, case by case, under the BAA Curve signs on every plan. Book a call with Curve.

Why does a direct-to-patient program need metrics for each partner?

Because the patient journey leaves the brand's hands at the partner. A patient sees an ad, completes a visit with a telehealth provider and fills at a pharmacy partner, and each partner holds its own step. A program can run through more than one provider. On March 31, 2026, Managed Healthcare Executive reported that Novo Nordisk had launched a subscription program for cash-paying patients prescribed Wegovy® (Novo Nordisk), and that “Novo Nordisk is offering the subscriptions through telehealth providers Ro, WeightWatchers and LifeMD” (Managed Healthcare Executive).

Insurance data won't fill the gap. HealthVerity, a real-world data company, wrote in January 2026 that patients who continue through direct-to-consumer programs “can disappear from closed payer claims data even though treatment has not stopped” (HealthVerity). So the numbers that show how the program performs at each partner come from the partners' own step events, matched to the campaigns that brought the patients, not from claims.

Which metrics should you track for each telehealth partner?

Seven numbers cover most programs. Each one is a rate or a cost for a group of patients, never a record about one person:

MetricHow to compute itWhat it shows
Match ratePartner events tied to an ad click, divided by all partner eventsWhether the other numbers can be trusted
Visit-to-consult rateConsults completed divided by visits startedWhere the intake step loses people
Paid-fill ratePaid fills divided by prescriptions writtenWhere patients stall between prescription and pharmacy
Time to first fillDays from completed consult to first paid fillFriction at the pharmacy handoff
Month-3 refill ratePatients with a paid refill at month 3, divided by patients who started in that cohortEarly persistence
Month-6 refill rateThe same at month 6Longer persistence
Cost per paid fillAd spend on the campaigns that brought patients to the partner, divided by the paid fills credited to themSpend efficiency through that partner

Read every metric by partner, by campaign and by start month. Put the match rate first: if one partner's events tie back to ad clicks far less often than another's, every cost metric for that partner will look worse for a reason that has nothing to do with patients. The usual causes are a click lost at the handoff from the brand site, an event without the campaign field, or two sides defining a step differently.

Why is paid-fill rate the core partner metric?

Because a prescription is not a patient on therapy until it is filled and paid. Visits and consults count activity; paid fills are where the program's spend turns into treatment. In a March 2026 Pharmaceutical Commerce interview, AssistRx's Jordan Armstrong put speed first, “getting that patient onto therapy as quickly as possible,” and the article lists “conversion rates, refill adherence” among the measures that show a program's value (Pharmaceutical Commerce).

Read paid-fill rate together with time to first fill. A partner whose patients fill slowly may have a pharmacy handoff problem, such as a missing shipping step or a payment page that fails on mobile, which both sides can fix once the number makes it visible. Prescription rate is deliberately not on the list: prescribing decisions belong to the clinician, and a partner metric should never reward more prescriptions.

How should you measure month-3 and month-6 retention by partner?

By cohort, in aggregate. Group patients who started in the same month through the same partner and campaign, then report the share with a paid refill at month 3 and at month 6. Nobody outside the partner needs a name for this: the partner reports the step and the campaign; report rates only for groups big enough to share. Month-6 numbers are only readable once a cohort is six months old, so early reads lean on month 3.

Expect the baseline to differ by cohort before any partner effect. IQVIA's February 2026 post on direct-to-patient programs cites a 180-day adherence analysis for Zepbound® (Eli Lilly) and Wegovy® (Novo Nordisk) with these averages (IQVIA, February 2026):

Cohort, as IQVIA describes itAverage days on therapy, of 180
Commercial, Zepbound (Pen)155
Commercial, Wegovy154
Zepbound (vial), direct-to-patient channels141
Zepbound Pen Cash Card128
Wegovy Cash Card121

IQVIA calls the vial channel “comparably persistent” and says the cash card cohorts “lag behind slightly.” These are averages across different products, forms and payment routes, not a verdict on any channel or provider. For partner metrics the lesson is simple: compare partners within the same product, form, start month and payment route, or the comparison mostly measures the mix.

What cohort caveats apply when comparing partners?

  • Patient mix. Partners reach different audiences through different channels, so their cohorts start in different places.
  • Product and form. Pen and vial cohorts differ in the IQVIA figures; keep each product form in its own cohort.
  • Plan length. Patients on a multi-month subscription and patients who buy one fill at a time aren't comparable at month 6.
  • Start month. A cohort that started during a supply change or a new offer can behave differently from one that didn't.
  • Small groups. Below a minimum group size, rates swing widely and can point to individuals; withhold them rather than report them.
  • Match rate. A partner with a low match rate looks worse on every cost metric until the plumbing is fixed.

What should a partner share, and what stays with the partner?

In this method, each partner reports a stripped-down event at each step (visit, consult, prescription, paid fill, refill) carrying the campaign that brought the patient, with no name or contact details. Names and contact details stay with the partner. The drugmaker receives aggregate results by channel, campaign and partner, and each partner sees its own results.

Ask for safeguards in the data agreement: a minimum group size below which results are withheld, coarse time windows such as weeks or months rather than exact dates, and a ban on any attempt to re-identify patients. Michelle Davey, CEO of Wheel, a founding partner in DiMe's direct-to-patient initiative, put the principle as “clear standards, clinical independence, and accountability from the start” (DiMe release). For how small-group rules work, see small-group rules.

Use partner metrics to run the program well, not to move patients toward one provider; patients keep choosing where they are seen. Data-sharing terms between a drugmaker and its partners raise legal questions of their own, so talk to your counsel before partner events start flowing.

How Curve Compliance helps

Curve Compliance supports this method. Telehealth and pharmacy partners can report step events such as consult, prescription, paid fill and refill through an incoming webhook or a file upload, and Curve credits each one to the original ad click. Curve keeps the ad click attached when a visitor leaves the brand site for a booking or intake step on another system, and outcomes recorded days later still match. Common booking tools are built in, and other systems are connected through setup by Curve's team.

The drugmaker receives aggregate results by channel, campaign and partner, including cost per paid fill, and month-3 and month-6 refills can be reported by partner in aggregate. Campaign Reporting puts Meta and Google Ads spend next to Curve-tracked outcomes per platform and campaign, with five attribution models. Partners connect once and see their own results, and the partner tools are open to every partner in the program.

Curve signs a BAA on every plan, holds SOC 2 Type II, and its team does the setup, typically live in about a week, case by case. The clinic-side version of cost per start is in how to calculate cost per started patient. See Curve conversion tracking and Curve for pharma and medical device teams, or book a call to plan partner metrics for your program.

For how partner step events become aggregate reports, see direct-to-patient pharma attribution.

Partner metrics are one part of the full method: how to measure a direct-to-patient program.

For how a partner sends and sees these numbers, see direct-to-patient partner reporting.

Sources, checked November 20, 2026: Managed Healthcare Executive, March 31, 2026; HealthVerity, January 14, 2026; Pharmaceutical Commerce, March 26, 2026; IQVIA, February 10, 2026; DiMe release, April 16, 2026.

Frequently Asked Questions

What are telehealth partner metrics?

They are the aggregate numbers a drugmaker uses to see how each telehealth and pharmacy partner in a direct-to-patient program turns visits into paid fills and refills. The core ones are paid-fill rate, time to first fill, month-3 and month-6 refill rates and cost per paid fill.

Why not compare partners on visits or prescriptions?

Visits and consults count activity, not patients on therapy, and prescribing decisions belong to the clinician. Paid fills and refills show whether patients actually start and stay.

How do you compare partners fairly?

Within the same cohort: the same product and form, start month, payment route and plan length. Check each partner's match rate first, since a low rate makes every cost metric look worse.

Do partners need to share patient names?

Not for this method. Each partner reports the step, the date and the campaign that brought the patient, with no name or contact details, and the drugmaker receives aggregate results.

What do the IQVIA retention numbers show?

In IQVIA's February 2026 post, commercial patients averaged 155 days on Zepbound pens over 180 days, the direct-to-patient vial channel 141 days, and the cash card cohorts 128 and 121 days (IQVIA, February 2026). The cohorts differ by product, form and payment route, so they set context, not targets.

What should partner metrics be used for?

To find and fix problems in the program, such as a slow pharmacy handoff or a broken intake step. They describe how the program performs, not where patients should be sent.

How does Curve Compliance help with partner metrics?

Curve takes in partner step events through incoming webhooks or file uploads, credits each to the original ad click, and puts Meta and Google Ads spend next to them in Campaign Reporting. Partners connect once and see their own results, and the partner tools are open to every partner in the program.

Talk to Curve Compliance

Book a call. Want paid-fill rate and month-3 and month-6 refills by partner, in aggregate? Curve's team does the setup for the partner events and Campaign Reporting, typically live in about a week, case by case, under the BAA Curve signs on every plan. Book a call with Curve.